#Anocca
From the lab to the patient 🔬🧑‍⚕️

4 years after our investment supported pioneering research, Anocca has reached a major milestone: delivering treatment to patients.

A powerful reminder of why we invest in innovation⤵️

go.eib.org/AnoccaSweden
October 5, 2026 at 1:36 PM
Chief executive Reagan Jarvis describes the role a branding agency had in naming his technology company

go.nature.com/4gS7Ac8
Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca
Chief executive Reagan Jarvis describes the role a branding agency had in naming his technology company.
go.nature.com
October 2, 2025 at 2:02 PM
#sthlmtech #biotech company #Anocca, an immunotherapy startup focused on pancreatic cancer, raised around $46M. Mellby Gård led, joined by AMF and Ramsbury. By @endpts endpoints.news/anocca-gets-... #NordicMade #LifeScience
Swedish biotech gets $46M to run early TCR cell therapy clinical trial
Anocca announced Monday that it secured a fresh SEK 440 million — or roughly $46 million — to run an early-stage trial of a cell therapy for KRAS mutant pancreatic cancer. ...
endpoints.news
August 18, 2025 at 8:14 PM
Through #InvestEU, we are investing in Europe’s future capital markets.

We have signed our first pre-IPO advisory agreement with Anocca, helping the company strengthen governance and get ready for a potential stock market listing.

👉 go.eib.org/Sweden_IPO
March 18, 2026 at 8:59 AM
Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca

Nature, Published online: 02 October 2025; doi:10.1038/d41586-025-02667-8Chief executive Reagan Jarvis describes the role a branding agency had in naming his technology company.
Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca
Nature, Published online: 02 October 2025; doi:10.1038/d41586-025-02667-8Chief executive Reagan Jarvis describes the role a branding agency had in naming his technology company.
drwebdomain.blog
October 2, 2025 at 5:07 PM
Anocca Announces Authorisation of Clinical Trial Application to Start First In ... - Yahoo Fina - goo.gl/alerts/8LvRpa #GoogleAlerts
Anocca Announces Authorisation of Clinical Trial Application to Start First In-Human Trial in Advanced Pancreatic Cancer
CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced Pancreatic Cancer at leading medical centres in Sweden...
goo.gl
March 18, 2025 at 4:16 PM
“This support is a very strong vote of confidence in the ability of Swedish and Nordic life sciences to build and compete globally," says Reagan Jarvis, CEO, Anocca. nordiclifescience.org/anocca-raise...
Anocca raises SEK 440 million – Interview with Reagan Jarvis, CEO - NLS
The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors.
nordiclifescience.org
August 18, 2025 at 7:13 AM
Feed: "PharmaTimes"
By: John Pinching on Thursday, June 11, 2026
Anocca doses first patients with precision TCR‑T therapy
Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial
pharmatimes.com
June 11, 2026 at 11:49 PM
Feed: "Nature"
By: Jacqui Thornton
Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca
Chief executive Reagan Jarvis describes the role a branding agency had in naming his technology company.
www.nature.com
October 3, 2025 at 10:03 AM
Feed: "Clinical Trials Arena"
By: gullapalli on Tuesday, August 19, 2025
Anocca secures $46m to support pancreatic cancer therapy trials
Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.
www.clinicaltrialsarena.com
August 19, 2025 at 10:08 PM
Feed: "Endpoints News"
By: Lei Lei Wu on Monday, August 18, 2025
Anocca gets $46M to run early TCR cell therapy clinical trial
Anocca announced Monday that it secured a fresh SEK 440 million — or roughly $46 million — to run an early-stage trial of a cell therapy for KRAS mutant pancreatic cancer. ...
endpoints.news
August 19, 2025 at 6:17 AM
Feed: "PharmaTimes"
By: John Pinching on Monday, March 17, 2025
Anocca announces authorisation pancreatic cancer trial
VIDAR-1 trial marks company's clinical-stage debut
pharmatimes.com
March 18, 2025 at 9:09 AM
Additional Funding Raises: #Midas $80M Series B; #FiscalNote $75M Post-IPO Debt; #Stark $62M; #Ivix $60M Series B; #TwinHealth $53M SeriesE; #Anocca $46M; #Medallion $43M Series C

Acquisitions: #AccentureSong > #Superdigital; #AIR > #OwensDesign; #Comply365 > #Beams
August 23, 2025 at 12:40 AM
Annoca has announced securing $46M to run an early stage TCR cell therapy trial.
endpoints.news/anocca-gets-...
Swedish biotech gets $46M to run early TCR cell therapy clinical trial
Anocca announced Monday that it secured a fresh SEK 440 million — or roughly $46 million — to run an early-stage trial of a cell therapy for KRAS mutant pancreatic cancer. ...
endpoints.news
August 18, 2025 at 12:05 PM
Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca

Anocca senior bioengineer Jonas Frey analyses data from an automated liquid-handling robot in one of the company’s research and development laboratories.Credit: Anocca The meaning behind our moniker Anocca, a…
Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca
Anocca senior bioengineer Jonas Frey analyses data from an automated liquid-handling robot in one of the company’s research and development laboratories.Credit: Anocca The meaning behind our moniker Anocca, a biotechnology firm in Södertälje, Sweden, develops precision T-cell immunotherapies to recognize cancer targets. It was co-founded by New Zealander Reagan Jarvis, a physician and biochemist who is now the company’s chief executive, and Mikael  Blomqvist, a Swedish entrepreneur who sits on the board of directors. Jarvis describes how they chose a name that, to them, felt memorable and distinctive, but “not too sciencey”.
n24usa.com
October 3, 2025 at 12:11 AM
لماذا قمنا بتسمية شركة التكنولوجيا الحيوية Anocca

يحلل Jonas Frey ، كبير ANOCCA ، Jonas Frey ، بيانات من روبوت تلقائي للمعالجة السائلة في أحد مختبرات الأبحاث والتطوير في الشركة.الائتمان: Anocca المعنى وراء لقبنا تقوم Anocca ، وهي شركة للتكنولوجيا الحيوية في Södertälje ، السويد ، بتطوير علاجات…
لماذا قمنا بتسمية شركة التكنولوجيا الحيوية Anocca
يحلل Jonas Frey ، كبير ANOCCA ، Jonas Frey ، بيانات من روبوت تلقائي للمعالجة السائلة في أحد مختبرات الأبحاث والتطوير في الشركة.الائتمان: Anocca المعنى وراء لقبنا تقوم Anocca ، وهي شركة للتكنولوجيا الحيوية في Södertälje ، السويد ، بتطوير علاجات مناعية للخلايا التائية الدقيقة للتعرف على أهداف السرطان. وقد شارك في تأسيسها نيوزيلاندر ريغان جارفيس ، الطبيب والكيميائي الحيوي الذي يشغل الآن منصب الرئيس التنفيذي للشركة ، وميكائيل بلومكفيست ، وهو رجل أعمال سويدي يجلس في مجلس إدارة المخرجين. يصف جارفيس كيف اختاروا اسمًا ، بالنسبة لهم ، شعروا بأنهم لا يُنسى ومميزًا ، ولكن "ليس العلم للغاية".
beiruttime-lb.com
October 2, 2025 at 9:01 PM
Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca
Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca
Nature, Published online: 02 October 2025; doi:10.1038/d41586-025-02667-8 Chief executive Reagan Jarvis describes the role a branding agency had in naming his technology company.
www.nature.com
October 2, 2025 at 1:40 PM